HUTCHMED and GSK Sign Deal for Dual-Targeted KRAS-EGFR Cancer Drug

HUTCHMED licenses HMPL-A830, a KRAS-EGFR ATTC, to GSK for $110M upfront. Trials start H2 2026 in colorectal, pancreatic and lung cancers.